Beyond PARP-POLθ as an anticancer target

被引:59
|
作者
Higgins, Geoff S. [1 ]
Boulton, Simon J. [2 ,3 ]
机构
[1] Univ Oxford, Inst Radiat Oncol, Canc Res UK Med Res Council Oxford, Old Rd,Campus Res Bldg,Roosevelt Dr, Oxford OX3 7DQ, England
[2] Francis Crick Inst, 1 Midland Rd, London NW1 1AT, England
[3] Artios Pharma Ltd, Babraham Res Campus, Cambridge CB22 3AT, England
关键词
POLYMERASE-THETA; REPAIR; RECOMBINATION; CANCER; OLAPARIB; THERAPY; TUMORS; TRIAL; CELLS; NHEJ;
D O I
10.1126/science.aar5149
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
引用
收藏
页码:1217 / +
页数:2
相关论文
共 50 条
  • [1] Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
    Curtin, Nicola J.
    Szabo, Csaba
    MOLECULAR ASPECTS OF MEDICINE, 2013, 34 (06) : 1217 - 1256
  • [2] PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention
    Zhu, Xiaolei
    Ma, Xiaodong
    Hu, Yongzhou
    CURRENT MEDICINAL CHEMISTRY, 2016, 23 (17) : 1756 - 1774
  • [3] Beyond PARP1: Ribosylation as a Target for Cancer Therapy
    Richon, Victoria
    ONCOLOGIST, 2018, 23 : S1 - S1
  • [4] Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
    Diana Zatreanu
    Helen M. R. Robinson
    Omar Alkhatib
    Marie Boursier
    Harry Finch
    Lerin Geo
    Diego Grande
    Vera Grinkevich
    Robert A. Heald
    Sophie Langdon
    Jayesh Majithiya
    Claire McWhirter
    Niall M. B. Martin
    Shaun Moore
    Joana Neves
    Eeson Rajendra
    Marco Ranzani
    Theresia Schaedler
    Martin Stockley
    Kimberley Wiggins
    Rachel Brough
    Sandhya Sridhar
    Aditi Gulati
    Nan Shao
    Luned M. Badder
    Daniela Novo
    Eleanor G. Knight
    Rebecca Marlow
    Syed Haider
    Elsa Callen
    Graeme Hewitt
    Joost Schimmel
    Remko Prevo
    Christina Alli
    Amanda Ferdinand
    Cameron Bell
    Peter Blencowe
    Chris Bot
    Mathew Calder
    Mark Charles
    Jayne Curry
    Tennyson Ekwuru
    Katherine Ewings
    Wojciech Krajewski
    Ellen MacDonald
    Hollie McCarron
    Leon Pang
    Chris Pedder
    Laurent Rigoreau
    Martin Swarbrick
    Nature Communications, 12
  • [5] Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
    Zatreanu, Diana
    Robinson, Helen M. R.
    Alkhatib, Omar
    Boursier, Marie
    Finch, Harry
    Geo, Lerin
    Grande, Diego
    Grinkevich, Vera
    Heald, Robert A.
    Langdon, Sophie
    Majithiya, Jayesh
    McWhirter, Claire
    Martin, Niall M. B.
    Moore, Shaun
    Neves, Joana
    Rajendra, Eeson
    Ranzani, Marco
    Schaedler, Theresia
    Stockley, Martin
    Wiggins, Kimberley
    Brough, Rachel
    Sridhar, Sandhya
    Gulati, Aditi
    Shao, Nan
    Badder, Luned M.
    Novo, Daniela
    Knight, Eleanor G.
    Marlow, Rebecca
    Haider, Syed
    Callen, Elsa
    Hewitt, Graeme
    Schimmel, Joost
    Prevo, Remko
    Alli, Christina
    Ferdinand, Amanda
    Bell, Cameron
    Blencowe, Peter
    Bot, Chris
    Calder, Mathew
    Charles, Mark
    Curry, Jayne
    Ekwuru, Tennyson
    Ewings, Katherine
    Krajewski, Wojciech
    MacDonald, Ellen
    McCarron, Hollie
    Pang, Leon
    Pedder, Chris
    Rigoreau, Laurent
    Swarbrick, Martin
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [6] Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
    Zatreanu, Diana A.
    Robinson, Helen M. R.
    Alkhatib, Omar
    Boursier, Marie
    Finch, Harry
    Geo, Lerin
    Grande, Diego
    Grinkevich, Vera
    Heald, Robert
    Langdon, Sophie
    Majithiya, Jayesh
    McWhirter, Claire
    Martin, Niall M. B.
    Moore, Shaun
    Neves, Joana
    Rajendra, Eeson
    Ranzani, Marco
    Schaedler, Theresia
    Stockley, Martin
    Wiggins, Kimberley
    Brough, Rachel
    Sridhar, Sandhya
    Gulati, Aditi
    Shao, Nan
    Badder, Luned M.
    Novo, Daniela
    Knight, Eleanor G.
    Marlow, Rebecca
    Haider, Syed
    Callen, Elsa
    Hewitt, Graeme
    Schimmel, Joost
    Prevo, Remko
    Alli, Christina
    Ferdinand, Amanda
    Bell, Cameron
    Blencowe, Peter
    Calder, Mathew
    Charles, Mark
    Curry, Jayne
    Ekwuru, Tennyson
    Ewings, Katherine
    Nussenzweig, Andre
    Tijsterman, Marcel
    Tutt, Andrew
    Boulton, Simon J.
    Higgins, Geoff S.
    Pettitt, Steve
    Smith, Graeme C. M.
    Lord, Christopher J.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [8] Targeting PARP inhibitor resistance with Polθ inhibitors
    Zatreanu, Diana
    Robinson, Helen
    Alkhatib, Omar
    Boursier, Marie
    Finch, Harry
    Geo, Lerin
    Grande, Diego
    Grinkevich, Vera
    Heald, Robert
    Langdon, Sophie
    Majithiya, Jayesh
    McWhirter, Claire
    Martin, Niall
    Moore, Shaun
    Neves, Joana
    Rajendra, Eeson
    Ranzani, Marco
    Schaedler, Theresia
    Stockley, Martin
    Wiggins, Kimberley
    Brough, Rachel
    Sridhar, Sandhya
    Gulati, Aditi
    Shao, Nan
    Badder, Luted
    Novo, Daniela
    Knight, Eleanor
    Marlow, Rebecca
    Haider, Syed
    Callen, Elsa
    Hewitt, Graeme
    Schimmel, Joost
    Prevo, Remko
    Alli, Christina
    Ferdinand, Amanda
    Bell, Cameron
    Blencowe, Peter
    Bot, Chris
    Calder, Mathew
    Charles, Mark
    Curry, Jayne
    Ekwuru, Tennyson
    Nussenzweig, Andre
    Tijsterman, Marcel
    Tutt, Andrew N.
    Boulton, Simon
    Higgins, Geoff
    Pettitt, Stephen J.
    Smith, Graeme C.
    Lord, Christopher J.
    CANCER RESEARCH, 2022, 82 (12)
  • [9] PARP inhibitors for anticancer therapy
    Curtin, Nicola
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2014, 42 : 82 - 88
  • [10] PARP inhibition: PARP1 and beyond
    Rouleau, Michele
    Patel, Anand
    Hendzel, Michael J.
    Kaufmann, Scott H.
    Poirier, Guy G.
    NATURE REVIEWS CANCER, 2010, 10 (04) : 293 - 301